Cargando…

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

BACKGROUND: A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1. OBJECTIVE: The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garimella, Tushar, Tao, Xiaolu, Sims, Karen, Chang, Yi-Ting, Rana, Jignasa, Myers, Elsa, Wind-Rotolo, Megan, Bhatnagar, Rahul, Eley, Timothy, LaCreta, Frank, AbuTarif, Malaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833906/ https://www.ncbi.nlm.nih.gov/pubmed/29255971 http://dx.doi.org/10.1007/s40268-017-0222-8

Ejemplares similares

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
por: Zhu, Li, et al.
Publicado: (2018)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

822 Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects
por: Garimella, Tushar, et al.
Publicado: (2014)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
por: Yin, Ophelia, et al.
Publicado: (2021)

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
por: Taki, Shinya, et al.
Publicado: (2018)

Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients
por: Tarao, Kazuo, et al.
Publicado: (2017)

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
por: Baba, Hayato, et al.
Publicado: (2016)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

A Review of Daclatasvir Drug–Drug Interactions
por: Garimella, Tushar, et al.
Publicado: (2016)

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
por: de Ruiter, Petra E, et al.
Publicado: (2018)

823 Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions
por: Miyashima, Yuichi, et al.
Publicado: (2016)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir
por: Sugiura, Ayumi, et al.
Publicado: (2017)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
por: Hong, Ying, et al.
Publicado: (2021)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
por: Kawakubo, Megumi, et al.
Publicado: (2018)

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019)

Daclatasvir and asunaprevir improves health‐related quality of life in Japanese patients infected with hepatitis C virus
por: Ikeda, Hiroki, et al.
Publicado: (2018)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
por: Lu, Yun, et al.
Publicado: (2018)

Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia
por: Takakusagi, Satoshi, et al.
Publicado: (2018)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019)

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017)

Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy
por: Uchida, Yoshihito, et al.
Publicado: (2018)

Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail
por: Lenoir, Camille, et al.
Publicado: (2021)

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
por: Cho, Byeong Wook, et al.
Publicado: (2017)

Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase
por: Gentles, Robert G.
Publicado: (2018)

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b
por: Matsumoto, Nobuyuki, et al.
Publicado: (2016)

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir
por: Friborg, Jacques, et al.
Publicado: (2014)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q40m62gkr2p4s8ut5vg1thte06